Current Status of Malaria and Anti-Malarial Drug Resistance in Sri Lanka
Current Status of Malaria and Anti-Malarial Drug Resistance in Sri Lanka
复制标题
斯里兰卡疟疾及抗疟药物耐药性现状
DOI：
10.4038/cjsbs.v37i1.493
复制
发表时间：
2009
影响因子：
--
通讯作者：
Olivier Jt Briet
中科院分区：
文献类型：
--
作者：
R. Rajakaruna;P. Amerasinghe;G. Galappaththy;F. Konradsen;Olivier Jt Briet
尽管疟疾在世界上大多数疟疾流行国家继续造成高发病率和死亡率，但目前在斯里兰卡并不是一个主要的健康问题。尽管疟疾发病率很低，但抗疟疾药物抗药性的发展和蔓延，加上最近武装冲突的增加，阻碍了有效保健服务的提供，将使斯里兰卡难以控制疟疾。自从1984年在丹布勒地区首次报道抗氯喹（CQ）恶性疟原虫以来，在各种流行区体内观察到的恶性疟原虫数量已增加到50%以上。与此一致，恶性疟原虫基因中存在导致CQ抗性的单核苷酸多态性（SNP）。有限数量的试验研究了二线药物周效磺胺/乙胺嘧啶（SP）对抗恶性疟原虫的疗效，并报告了一些耐药性病例。此外，恶性疟原虫基因中存在负责SP抗性的SNP，并且可能构成SP抗性发展的标志。对于间日疟原虫，抗药性在斯里兰卡尚未被记录为一个问题，然而，间日疟原虫种群中SP耐药SNP的流行率似乎很高，尽管SP不直接用于间日疟原虫感染，但可能构成风险。持续监测体内药物疗效，以及通过测量与耐药性相关的SNP的患病率是有待解决的主要问题。doi：10.4038/cjsbs.v37i1.493 Cey.《科学杂志》（生物。Sci.）37（1）：15-22，2008年
Even though malaria continues to cause high morbidity and mortality in most of the malaria endemic countries in the world, it is currently not a major health problem in Sri Lanka. Despite the low malaria incidence, the development and spread of anti-malarial drug resistance, combined with a recent increase in the armed conflict hindering provision of effective health services will make it difficult to control malaria in Sri Lanka. Since chloroquine (CQ) resistant Plasmodium falciparum was first reported from Dambulla area in 1984, the number has increased to more than 50% observed in vivo from various endemic areas. In concordance with this, single nucleotide polymorphisms (SNPs) in genes of P. falciparum responsible for CQ resistance are present. A limited number of trials have investigated the efficacy of the second line drug, sulfadoxine/ pyrimethamine (SP) against P. falciparum and a few cases of resistance have been reported. Moreover, SNPs in P. falciparum genes responsible for SP resistance are present and may constitute a sign of evolving SP resistance development. For P. vivax , drug resistance is not yet recorded as a problem in Sri Lanka, however the prevalence of SP resistant SNPs in P. vivax populations seems high and may pose a risk despite that SP is not used directly against P. vivax infections. Continuous monitoring of drug efficacy in vivo , as well by measuring the prevalence of SNPs related to drug resistance are major issues to be addressed. doi: 10.4038/cjsbs.v37i1.493 Cey. J. Sci. (Bio. Sci.) 37 (1): 15-22, 2008
影响因子：
16
作者：
Fidock, DA;Nomura, T;Wellems, TE
通讯作者：
Wellems, TE
影响因子：
6.4
作者：
Kublin, JG;Dzinjalamala, FK;Plowe, CV
通讯作者：
Plowe, CV
DOI：
10.4269/ajtmh.2003.69.247
发表时间：
2003-09-01
影响因子：
3.3
作者：
Kyabayinze, D;Cattamanchi, A;Dorsey, G
通讯作者：
Dorsey, G